Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

NCT01061723 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Sarilumab
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]